Literature DB >> 25966274

Mangiferin induces cell cycle arrest at G2/M phase through ATR-Chk1 pathway in HL-60 leukemia cells.

Z G Peng1, Y B Yao2, J Yang2, Y L Tang2, X Huang2.   

Abstract

This study aimed to determine the effect of mangiferin on the cell cycle in HL-60 leukemia cells and expression of the cell cycle-regulatory genes Wee1, Chk1 and CDC25C and to further investigate the molecular mechanisms of the antileukemic action of mangiferin. The inhibitory effect of mangiferin on HL-60 leukemia cell proliferation was determined by the MTT assay. The impact of mangiferin on the HL-60 cell cycle was evaluated by flow cytometry. After the cells were treated with different concentrations of mangiferin, the expression levels of Wee1, Chk1 and CDC25C mRNA were determined by RT-PCR, and Western blot was used to evaluate the expression levels of cdc25c, cyclin B1, and Akt proteins. The inhibition of HL-60 cell growth by mangiferin was dose- and time-dependent. After treatment for 24 h, cells in G2/M phase increased, and G2/M phase arrest appeared with increased mRNA expression of Wee1, Chk1 and CDC25C. Mangiferin inhibited Chk1 and cdc25c mRNA expression at high concentrations and induced Wee1 mRNA expression in a dose-dependent manner. It significantly inhibited ATR, Chk1, Wee1, Akt, and ERK1/2 phosphorylation but increased cdc2 and cyclin B1 phosphorylation. Furthermore, mangiferin reduced cdc25c, cyclin B1, and Akt protein levels while inducing Wee1 protein expression. It also antagonized the phosphorylation effect of vanadate on ATR, and the phosphorylation effect of EGF on Wee1. These findings indicated that mangiferin inhibits cell cycle progression through the ATR-Chk1 stress response DNA damage pathway, leading to cell cycle arrest at G2/M phase in leukemia cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25966274     DOI: 10.4238/2015.May.12.2

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  7 in total

1.  Identification of hub genes and pathways associated with bladder cancer based on co-expression network analysis.

Authors:  Dong-Qing Zhang; Chang-Kuo Zhou; Shou-Zhen Chen; Yue Yang; Ben-Kang Shi
Journal:  Oncol Lett       Date:  2017-05-26       Impact factor: 2.967

Review 2.  Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary.

Authors:  Hiroshi Kobayashi; Naoki Kawahara; Kenji Ogawa; Yuki Yamada; Kana Iwai; Emiko Niiro; Sachiko Morioka
Journal:  Biomed Rep       Date:  2018-06-20

Review 3.  Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds.

Authors:  Abedul Haque; Daniel Brazeau; Arm R Amin
Journal:  Eur J Cancer       Date:  2021-04-14       Impact factor: 9.162

Review 4.  Mangiferin: a natural miracle bioactive compound against lifestyle related disorders.

Authors:  Muhammad Imran; Muhammad Sajid Arshad; Masood Sadiq Butt; Joong-Ho Kwon; Muhammad Umair Arshad; Muhammad Tauseef Sultan
Journal:  Lipids Health Dis       Date:  2017-05-02       Impact factor: 3.876

Review 5.  Mangiferin as New Potential Anti-Cancer Agent and Mangiferin-Integrated Polymer Systems-A Novel Research Direction.

Authors:  Svetlana N Morozkina; Thi Hong Nhung Vu; Yuliya E Generalova; Petr P Snetkov; Mayya V Uspenskaya
Journal:  Biomolecules       Date:  2021-01-09

Review 6.  Mangiferin and Cancer: Mechanisms of Action.

Authors:  Fuchsia Gold-Smith; Alyssa Fernandez; Karen Bishop
Journal:  Nutrients       Date:  2016-06-28       Impact factor: 5.717

7.  The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells.

Authors:  Huang-Ju Tu; Yi-Jyun Lin; Min-Wu Chao; Ting-Yi Sung; Yi-Wen Wu; Yi-Ying Chen; Mei-Hsiang Lin; Jing-Ping Liou; Shiow-Lin Pan; Chia-Ron Yang
Journal:  Clin Epigenetics       Date:  2018-12-29       Impact factor: 6.551

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.